© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Expert hematologist-oncologist Rafael Fonseca, MD, reviews the diagnosis and management of an 81-year-old-man who presents with transplant-ineligible multiple myeloma.
April 29th 2022
Rafael Fonseca, MD, provides details on a patient case of transplant-ineligible multiple myeloma and reviews the selection of frontline triplet versus doublet therapy.
Expert perspectives on updated data from the MAIA trial in newly diagnosed transplant-ineligible multiple myeloma and how this can be applied to clinical practice.
Practical advice on strategies to improve care for patients with transplant-ineligible multiple myeloma regarding induction and maintenance therapy, and aiming for deep and durable responses.
Rafael Fonseca, MD, shares an overview of the treatment armamentarium for patients with relapsed/refractory multiple myeloma.
Shared insight on two novel CAR T-cell therapies, cilta-cel and ide-cel, that have been tested in multiply relapsed multiple myeloma.
Expert perspectives on two bispecific antibodies, teclistamab and talquetamab, that have been investigated in multiply relapsed multiple myeloma.
Before closing out his discussion on transplant-ineligible multiple myeloma, Rafael Fonseca, MD, considers the future roles of CAR T-cell and bispecific antibody therapies.